Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) EBT (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of EBT readings, the most recent being -$10.0 million for Q1 2026.

  • Quarterly EBT fell 30.31% to -$10.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$35.5 million through Mar 2026, down 31.26% year-over-year, with the annual reading at -$33.1 million for FY2025, 35.44% down from the prior year.
  • EBT hit -$10.0 million in Q1 2026 for DiaMedica Therapeutics, down from -$9.1 million in the prior quarter.
  • Across five years, EBT topped out at -$3.1 million in Q3 2022 and bottomed at -$10.0 million in Q1 2026.
  • Average EBT over 5 years is -$5.9 million, with a median of -$5.1 million recorded in 2024.
  • The largest annual shift saw EBT rose 11.36% in 2022 before it tumbled 54.29% in 2024.
  • DiaMedica Therapeutics' EBT stood at -$3.7 million in 2022, then tumbled by 37.26% to -$5.1 million in 2023, then tumbled by 54.29% to -$7.9 million in 2024, then decreased by 14.91% to -$9.1 million in 2025, then dropped by 10.14% to -$10.0 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's EBT are -$10.0 million (Q1 2026), -$9.1 million (Q4 2025), and -$8.6 million (Q3 2025).